
My top ten tips for graduating fellows and faculty entering and continuing “early career” as I am transitioning into “mid-career”. A thread:

Cardiologist @MidAmericaHeart, building programs to implement therapies, advance discovery, and foster innovation for patients suffering from heart disease.

My top ten tips for graduating fellows and faculty entering and continuing “early career” as I am transitioning into “mid-career”. A thread:

Finerenone versus Steroidal MRAs in Type 2 Diabetes and Chronic Kidney Disease without Prior Heart Failure Finerenone was associated with a lower 18-month risk of all-cause death compared with steroidal MRAs in patients aged ≥18 years with T2D and CKD without prior HF, who received an SGLT2 inhibitor as first-line therapy; however, residual confounding cannot be excluded, and these findings should be considered hypothesis-generating. @mvaduganathan @gcfmd @SJGreene_md @AndrewJSauer @hfcollaboratory academic.oup.com/eschf/advan…

I wonder if the Microsoft Outlook engineers are stuck in their own vicious cycle of Authenticator prompts?

I have to admit, having Microsoft Teams and Outlook down has been surprisingly therapeutic. Any chance the Epic In Basket servers are feeling a little under the weather too?

AI meets Heart Failure in the November issue of JCF 🫀 Our Focus Issue, Artificial Intelligence and Heart Failure: A Critical Juncture, explores the opportunities and challenges of AI in heart failure research and care. Read the full issue: onlinejcf.com/current


Presented at #ScientificSessions26: In patients with atrioventricular block, left bundle-branch pacing resulted in a lower incidence of a composite of death, hospitalization for heart failure, or pacing-induced cardiomyopathy than right ventricular pacing. Full OptimPacing trial results: nej.md/4favsI9 @AHAScience

💉 CAMEO-SEMA 👥 81 with obesity + HFpEF; 58% women ⚖️ Semaglutide vs placebo 📊 52wk exercise PAWP −10.6 mmHg (95% CI −13.3 to −8.0) ✅ Mechanistic support; small trial 🔗 nature.com/articles/s41591-0… #AHA26 #ScientificSessions26 #CVPrev

Are people with obesity and HFpEF getting better with glp1 drugs because their hearts are better, or is it just feeling better from wt loss? Two companion papers @NatureMedicine from placebo controlled RCT show that their HF really is better with pcwp and LA strain by MRI.

Effects of #Sotatercept on Cardiac Structure and Function in Combined Post- and Precapillary Pulmonary Hypertension in #HFpEF : Analysis of the #CADENCE Study ahajournals.org/doi/10.1161/… #ScientificSessions26 @AHAScience @AHAMeetings @CircAHA

Congrats @GLewisCardiol & team for important study of IV iron w FDI in HFpEF. Improving peak VO2 and other pt centered endpoints. Fun to write accompanying editorial Now we need to finish ICONIC and INFUSE @FudimMarat @AndrewPAmbrosy @DCRINews #ScientificSessions26

Presented at #ScientificSessions26: In patients with type 2 diabetes and high cardiovascular risk, a systolic blood-pressure target below 120 mm Hg did not result in fewer major cardiovascular events than a target below 140 mm Hg. Full OPTIMAL-DIABETES trial results: nej.md/3UZYKCy @AHAScience

When a claim of noninferiority hides factual inferiority! Data do not support statin discontinuation is safe with respect to MACE.
Presented at #ScientificSessions26: In older adults with at least two chronic conditions and no known atherosclerotic cardiovascular disease, statin discontinuation was noninferior to continuation for a composite of myocardial infarction, stroke, or death at 2 years. Full STREAM trial results: nej.md/47U1X9N @AHAScience

Trending on NEJM.org: 𝐓𝐀𝐕𝐑 𝐢𝐧 𝐏𝐚𝐭𝐢𝐞𝐧𝐭𝐬 𝐰𝐢𝐭𝐡 𝐌𝐨𝐝𝐞𝐫𝐚𝐭𝐞 𝐀𝐨𝐫𝐭𝐢𝐜 𝐒𝐭𝐞𝐧𝐨𝐬𝐢𝐬 𝐰𝐢𝐭𝐡 𝐀𝐭-𝐑𝐢𝐬𝐤 𝐅𝐞𝐚𝐭𝐮𝐫𝐞𝐬 (𝐏𝐑𝐎𝐆𝐑𝐄𝐒𝐒 𝐓𝐫𝐢𝐚𝐥) by P. Généreux et al. In patients with moderate aortic stenosis and at-risk features, the percentage who died or had a heart-failure event within 2 years was lower with transcatheter aortic-valve replacement than with surveillance (16.7% vs. 23.9%). Read the article: nej.md/4eUv9kA

💊 Quadruple GDMT for HFrEF at Cost Plus generic prices: 💵 $0.79/day · $23.83/mo · $290/yr 📉 ↓87% HF 🏨, ↓61% all-cause 🏨 🏥 Avoided hospital costs dwarf the drug cost ✅ Extraordinary value. 🎯 Get every eligible patient on all 4! ❤️ #GDMT @costplusdrugs @mcuban

Thank you, @AHajduczok, for having me on your podcast! Will I ever listen to it? Absolutely not. 😂 Nothing more uncomfortable than listening to yourself talk. But hopefully there are a few pearls of wisdom buried in here @DukeHeartCenter @DCRINews @DrMarthaGulati @dranulala
Episode 6: Moving the Needle in Medicine w/ guest @robmentz is now live! We talk all things mentorship, career challenges both inside and outside of the hospital, building teams, heart failure leadership, and taking over as editor-in-chief for the @JCardFail. Check it out!!! hcplive.com/view/moving-the-…